These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
366 related articles for article (PubMed ID: 29098361)
1. New agents in the Treatment of Myeloma Bone Disease. Ring ES; Lawson MA; Snowden JA; Jolley I; Chantry AD Calcif Tissue Int; 2018 Feb; 102(2):196-209. PubMed ID: 29098361 [TBL] [Abstract][Full Text] [Related]
2. Myeloma bone disease: pathogenesis, current treatments and future targets. Walker RE; Lawson MA; Buckle CH; Snowden JA; Chantry AD Br Med Bull; 2014 Sep; 111(1):117-38. PubMed ID: 25190762 [TBL] [Abstract][Full Text] [Related]
3. [Bone disease in multiple myeloma]. Irisawa H Nihon Rinsho; 2015 Jan; 73(1):42-6. PubMed ID: 25626302 [TBL] [Abstract][Full Text] [Related]
4. The role of bone-modifying agents in myeloma bone disease. Lu H; Pundole X; Lee HC JBMR Plus; 2021 Aug; 5(8):e10518. PubMed ID: 34368608 [TBL] [Abstract][Full Text] [Related]
5. Myeloma bone disease. Sezer O Hematology; 2005; 10 Suppl 1():19-24. PubMed ID: 16188625 [TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms, current management and next generation therapy in myeloma bone disease. Heusschen R; Muller J; Duray E; Withofs N; Bolomsky A; Baron F; Beguin Y; Menu E; Ludwig H; Caers J Leuk Lymphoma; 2018 Jan; 59(1):14-28. PubMed ID: 28573897 [TBL] [Abstract][Full Text] [Related]
7. Multiple Myeloma and Bone: The Fatal Interaction. Marino S; Roodman GD Cold Spring Harb Perspect Med; 2018 Aug; 8(8):. PubMed ID: 29229668 [TBL] [Abstract][Full Text] [Related]
8. The use of bone-modifying agents in multiple myeloma. Hussain M; Khan F; Al Hadidi S Blood Rev; 2023 Jan; 57():100999. PubMed ID: 36050125 [TBL] [Abstract][Full Text] [Related]
9. Biology and treatment of myeloma related bone disease. Terpos E; Christoulas D; Gavriatopoulou M Metabolism; 2018 Mar; 80():80-90. PubMed ID: 29175022 [TBL] [Abstract][Full Text] [Related]
10. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention. Kupisiewicz K Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989 [TBL] [Abstract][Full Text] [Related]
11. An Evidence-Based Approach to Myeloma Bone Disease. Bingham N; Reale A; Spencer A Curr Hematol Malig Rep; 2017 Apr; 12(2):109-118. PubMed ID: 28243849 [TBL] [Abstract][Full Text] [Related]
12. Myeloma Bone Disease: A Comprehensive Review. Mukkamalla SKR; Malipeddi D Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34201396 [TBL] [Abstract][Full Text] [Related]
14. A functional three-dimensional microphysiological human model of myeloma bone disease. Visconti RJ; Kolaja K; Cottrell JA J Bone Miner Res; 2021 Oct; 36(10):1914-1930. PubMed ID: 34173283 [TBL] [Abstract][Full Text] [Related]
15. Myeloma bone disease: Progress in pathogenesis. Xi H; An R; Li L; Wang G; Tao Y; Gao L Prog Biophys Mol Biol; 2016 Nov; 122(2):149-155. PubMed ID: 27496181 [TBL] [Abstract][Full Text] [Related]
16. Pathophysiology of myeloma bone disease. Esteve FR; Roodman GD Best Pract Res Clin Haematol; 2007 Dec; 20(4):613-24. PubMed ID: 18070709 [TBL] [Abstract][Full Text] [Related]
17. Targeting the bone microenvironment in multiple myeloma. Roodman GD J Bone Miner Metab; 2010 May; 28(3):244-50. PubMed ID: 20127498 [TBL] [Abstract][Full Text] [Related]
18. Tumor-host cell interactions in the bone disease of myeloma. Fowler JA; Edwards CM; Croucher PI Bone; 2011 Jan; 48(1):121-8. PubMed ID: 20615487 [TBL] [Abstract][Full Text] [Related]
19. Bone Disease in Multiple Myeloma. Eda H; Santo L; David Roodman G; Raje N Cancer Treat Res; 2016; 169():251-270. PubMed ID: 27696267 [TBL] [Abstract][Full Text] [Related]